<DOC>
	<DOCNO>NCT02929797</DOCNO>
	<brief_summary>A Prospective Study Efficacy Safety CD8+NKG2D+ AKT cell immunotherapy pancreatic cancer patient treat adjuvant chemotherapy .</brief_summary>
	<brief_title>Immunotherapy CD8+NKG2D+ AKT Cell With Chemotherapy Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Diagnosed stage IIIII pancreatic ductal adenocarcinoma patient pathologic histology ; 2 . Pancreatic cancer radical resection ; 3 . Eastern Cooperative Oncology Group Performance Status le 2 ; 4 . Without radiotherapy neoadjuvant chemotherapy ; 5 . The man gestation lactation woman Age 18 80 year old ; 6 . Bone marrow function well : ANC 1.5*10^9/ L , PLT 100*10^9/LHgb 9 g/dL ; 7 . Blood biochemical indicator : AST（SGOT）less 1.5 ULNALT（SGPT）less 1.5 ULN , TBIL le 1.5 ULN ; 8 . PT PPT normal range ; 9 . Three month prior clinical research receive clinical research trial ; 10. patient voluntary , willing sign inform consent . 1 . Patients malignant tumor past five year ; 2 . Active viral bacterial infection control appropriate antiinfection treatment ; 3 . Known HIV infection , active hepatitis B virus hepatitis C virus infection ; 4 . Known allergy kind component study drug ; 5 . History connective tissue disease ( Such lupus , scleroderma , nodular arteritis ) ; 6 . Patients history interstitial pneumoniaSlowly progressive difficulty breathe hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia A variety allergy ; 7 . Suffering mental illness illness , heart lung disease , diabetes , etc . control , cope study treatment monitoring requirement ; 8 . At time Patients participate use interventional medicine clinical research checker .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>